48
נקבה
נשואה
****
מלאה
מיידית
תיכונית, מקצועית, תואר ראשון, תואר שני
עברית
אנגלית
רוסית
אין פרטים זמינים
אין פרטים זמינים
Education
2012 - 2018 Postdoctoral fellowship, Cancer Research and Personalized Medicine, Bar-Ilan University
2007 - 2012 PhD Neuroscience, laboratory of Prof. Youdim, Technion - Israel Institute of Technology
2003 - 2007 MSc, Neuroscience, laboratory of Prof. Youdim, Technion - Israel Institute of Technology
1999 - 2003 BSc, Laboratory Medicine, Technion, Israel Institute of Technology
השכלה
דיפלומה
Patents
2021 COMBINATIONs OF IRESISTAT3 DUAL MODULATORS AND ANTI-CANCER AGENTS FOR TREATING CANCER, Publication Number 20210220297
2011 CORROLES FOR NEUROPROTECTION AND NEURORESCUE, Patent application number 20110098262
ניסיון תעסוקתי
Experience
2021 - 2023 Researcher and laboratory manager, Clinical Research Institute at Rambam (CRIR)
● Identification and characterization of molecular drivers of cancer formation and metastasis, using CRISPR Screens
● Establishment and verification of modular CRISPR-CAS9-based mouse cancer models for studying candidate driver gene function, identification of novel candidate compounds, and analysis of their impact on metastasis in mouse cancer models.
● Responsible for administrative and technical functions of laboratory management.
2020 - 2021 Project Manager, Vivox
● Worked with genetically modified and diseased induced rodent models, performed variety of surgical procedures on research animals, administered injections, took vital signs of animals, collected and processed tissue, body fluids, and biopsies, etc.
● Maintenance records of all procedures, animal use, protocol compliance, and integrity of the animal database in accordance with IACUC and GLP requirements.
2014 - 2020 Senior researcher, TyrNovo/Purple Biotech
● Establishment and management PDX (Patient Derived Xenograft) unit at Bar Ilan University and the Technion.
● Development of PDX and humanized PDX tumor models in immunodeficient mice
● Development of a cancer treatment that has the potential to prevent and overcome drug resistance in various cancer types when used in combination with existing agents, and investigation of its mechanism of action; preparation and submission of protocols to FDA.
2011 - 2012 Research assistant, Pharmacology, laboratory of Prof. Youdim, Faculty of Medicine at Technion - Israel Institute of Technology
● Examination of the novel multi-functional compounds for their potential therapeutic utility in the treatment of ALS, Alzheimer's, and aging, including their effects on cognitive/non-cognitive behaviors, molecular signaling pathways involved, and general metabolic functions.
● 10+ years of experience as a Senior Researcher and Laboratory manager.
● 6+ years experience in the pharmaceutical industry.
● PhD in Neuroscience, Technion.
● Specializing in preclinical in vitro and in vivo studies of therapeutic candidates.
● Identified and characterized molecular drivers of cancer using CRISPR Screens and CRISPR-CAS9-based mouse cancer models.
● Managed the PDX unit at Bar Ilan University and the Technion.
● Developed PDX and humanized PDX tumor models in immunodeficient mice.
● Investigated a cancer treatment for overcoming drug resistance, and prepared FDA protocols.
● Examined multi-functional compounds for therapeutic utility in ALS, Alzheimer's, and aging.
● Skilled in planning, designing, developing, and executing research protocols as well as preparation and editing material for publication, presentation, and submission.
● Postdoctoral Fellowship, Cancer Research and Personalized Medicine, Bar-Ilan University.
● Published 20+ highly cited scientific publications in the fields of neuroscience, neuropharmacology, and cancer pharmacology.
● Co-author of 3 patents, two of which are undergoing clinical trials
Selected publications
October 2021 IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapy, Nature Cancer
July 2018 NT219, a novel dual inhibitor of STAT3 and IRS1/2 converts immuno-oncology resistant tumors to responders, Cancer Research
2012 Book: “Novel multi-target therapies for neurodegenerative diseases treatment”, Lambert Academic Publishing
April 2012 The Novel Multi-Target Iron Chelating-Radical Scavenging Compound M30 Possess Beneficial Effects on Major Hallmarks of Alzheimers’ Disease, Antioxidants and Redox Signaling
April 2010 Metallocorroles as cytoprotective agents against oxidative and nitrative stress in cellular models of neurodegeneration, Journal of Neurochemistry
August 2009 Neuroprotective and neurogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and a transgenic mouse model of amyotrophic lateral sclerosis, The FASEB Journal
